Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
BioNTech is terminating its mid-stage trial of autogene cevumeran, an mRNA-based cancer vaccine co-developed with Roche's Genentech, after an independent safety board flagged a survival imbalance between treatment arms in high-risk colorectal cancer patients. The board concluded further continuation was unlikely to change the efficacy outcome. The news sent BioNTech's U.S.-listed shares down nearly 9%.
BioNTech's mRNA cancer vaccine hits a wall in colorectal cancer
BioNTech is shutting down its Phase 2 trial of autogene cevumeran, an experimental mRNA-based cancer vaccine developed jointly with Roche's Genentech, after an independent data safety monitoring board recommended stopping the study. The trial was testing the immunotherapy as an adjuvant monotherapy in patients with high-risk stage II or III colorectal cancer who had tumors surgically removed but remained ctDNA-positive — a marker indicating residual cancer risk.
The board's decision came after identifying a numerical imbalance in overall survival between the treatment arms, concluding that continuing the trial was unlikely to alter the efficacy outcome. The news rattled investors, sending BioNTech's U.S.-listed shares down nearly 9%.
Key Takeaways:
Why it matters: mRNA cancer vaccines have been one of the most closely watched frontiers in oncology. This trial failure is a notable setback for the field and raises questions about the specific utility of mRNA-based immunotherapy in ctDNA-positive colorectal cancer patients.
